{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:35Z","timestamp":1793643335406,"version":"4.5.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10067-020-04996-7","type":"journal-article","created":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T05:02:46Z","timestamp":1582347766000},"page":"1415-1421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Effects of rituximab therapy on B cell differentiation and depletion"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-3223","authenticated-orcid":false,"given":"L.","family":"Bergantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"d\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vagaggini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sestini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,22]]},"reference":[{"issue":"10","key":"4996_CR1","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG (2017) Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 34(10):2232\u20132273. https:\/\/doi.org\/10.1007\/s12325-017-0612-x","journal-title":"Adv Ther"},{"key":"4996_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ctrv.2016.11.015","volume":"53","author":"F Pavanello","year":"2017","unstructured":"Pavanello F, Zucca E, Ghielmini M (Feb. 2017) Rituximab: 13 open questions after 20years of clinical use. Cancer Treat Rev 53:38\u201346. https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.015","journal-title":"Cancer Treat Rev"},{"key":"4996_CR3","doi-asserted-by":"publisher","unstructured":"Lee I et al (2019) Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma. Ann Nucl Med. https:\/\/doi.org\/10.1007\/s12149-019-01401-5","DOI":"10.1007\/s12149-019-01401-5"},{"key":"4996_CR4","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Mu\u00f1oz R et al (2019) Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.16227","DOI":"10.1111\/bjh.16227"},{"key":"4996_CR5","doi-asserted-by":"publisher","unstructured":"Cylwik B, Gruszewska E, Gindzienska-Sieskiewicz E, Kowal-Bielecka O, Chrostek L (2019) Serum profile of transferrin isoforms in rheumatoid arthritis treated with biological drugs. Clin Biochem. https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.10.005","DOI":"10.1016\/j.clinbiochem.2019.10.005"},{"key":"4996_CR6","doi-asserted-by":"publisher","unstructured":"Fui A et al (2019) Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J. https:\/\/doi.org\/10.1111\/imj.14306","DOI":"10.1111\/imj.14306"},{"key":"4996_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40620-014-0135-3","volume":"28","author":"D Geetha","year":"2015","unstructured":"Geetha D, Kallenberg C, Stone JH, Salama AD, Appel GB, Duna G, Brunetta P, Jayne D (2015) Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol 28:17\u201327. https:\/\/doi.org\/10.1007\/s40620-014-0135-3","journal-title":"J Nephrol"},{"key":"4996_CR8","doi-asserted-by":"publisher","unstructured":"Hill A, Hill QA (2018) Autoimmune hemolytic anemia. Hematology. American Society of Hematology. Educ Program (1):382\u2013389. https:\/\/doi.org\/10.1182\/asheducation-2018.1.382","DOI":"10.1182\/asheducation-2018.1.382"},{"issue":"1","key":"4996_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjh.14515","volume":"177","author":"N Cooper","year":"2017","unstructured":"Cooper N (2017) State of the art \u2013 how I manage immune thrombocytopenia. Br J Haematol 177(1):39\u201354. https:\/\/doi.org\/10.1111\/bjh.14515","journal-title":"Br J Haematol"},{"issue":"1","key":"4996_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10067-010-1630-0","volume":"30","author":"AF Jansson","year":"2011","unstructured":"Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H, Kleinert D, Pape L, Girschick HJ, Foeldvari I, Haffner D, Haas JP, Moebius D, Foell D, Peitz J, Grote V (Jan. 2011) B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 30(1):87\u201397. https:\/\/doi.org\/10.1007\/s10067-010-1630-0","journal-title":"Clin Rheumatol"},{"issue":"12","key":"4996_CR11","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s10067-017-3848-6","volume":"36","author":"JT Einarsson","year":"2017","unstructured":"Einarsson JT, Evert M, Geborek P, Saxne T, Lundgren M, Kapetanovic MC (Dec. 2017) Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies. Clin Rheumatol 36(12):2743\u20132750. https:\/\/doi.org\/10.1007\/s10067-017-3848-6","journal-title":"Clin Rheumatol"},{"key":"4996_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/JBM.S190784","volume":"10","author":"R Mohammed","year":"2019","unstructured":"Mohammed R, Milne A, Kayani K, Ojha U (Feb. 2019) How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin\u2019s lymphomas. J Blood Med 10:71\u201384. https:\/\/doi.org\/10.2147\/JBM.S190784","journal-title":"J Blood Med"},{"issue":"6","key":"4996_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, Semenzato G, Rambaldi A, Fo\u00e0 R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, Zaja F, Regazzi M (Nov. 2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs 5(6):826\u2013837. https:\/\/doi.org\/10.4161\/mabs.26008","journal-title":"mAbs"},{"issue":"3","key":"4996_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000358887","volume":"126","author":"R Evans","year":"2014","unstructured":"Evans R, Salama AD (2014) Update on rituximab: an established treatment for all immune-mediated kidney diseases? Nephron Clin Pract 126(3):97\u2013109. https:\/\/doi.org\/10.1159\/000358887","journal-title":"Nephron Clin Pract"},{"issue":"6","key":"4996_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","volume":"27","author":"MB Regazzi","year":"2005","unstructured":"Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, Zaja F, Montagna M, Morra E, Lazzarino M (Dec. 2005) Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit 27(6):785\u2013792. https:\/\/doi.org\/10.1097\/01.ftd.0000184162.60197.c1","journal-title":"Ther Drug Monit"},{"issue":"8","key":"4996_CR16","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/bcp.13271","volume":"83","author":"S Rozman","year":"2017","unstructured":"Rozman S, Grabnar I, Novakovi\u0107 S, Mrhar A, Jezer\u0161ek Novakovi\u0107 B (Aug. 2017) Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol 83(8):1782\u20131790. https:\/\/doi.org\/10.1111\/bcp.13271","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4996_CR17","doi-asserted-by":"publisher","first-page":"R161","DOI":"10.1186\/ar3901","volume":"14","author":"H-P Brezinschek","year":"2012","unstructured":"Brezinschek H-P, Rainer F, Brickmann K, Graninger WB (2012) B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther 14(4):R161. https:\/\/doi.org\/10.1186\/ar3901","journal-title":"Arthritis Res Ther"},{"key":"4996_CR18","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.3389\/fimmu.2019.02221","volume":"10","author":"A von Borstel","year":"2019","unstructured":"von Borstel A et al (2019) CD27+CD38hi B cell frequency during remission predicts relapsing disease in granulomatosis with Polyangiitis patients. Front Immunol 10:2221. https:\/\/doi.org\/10.3389\/fimmu.2019.02221","journal-title":"Front Immunol"},{"issue":"3","key":"4996_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/art.30152","volume":"63","author":"EM Vital","year":"2011","unstructured":"Vital EM et al (2011) Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 63(3):603\u2013608. https:\/\/doi.org\/10.1002\/art.30152","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4996_CR20","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/art.27359","volume":"62","author":"EM Vital","year":"2010","unstructured":"Vital EM et al (2010) Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 62(5):1273\u20131279. https:\/\/doi.org\/10.1002\/art.27359","journal-title":"Arthritis Rheum"},{"issue":"25","key":"4996_CR21","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JCW Edwards","year":"2004","unstructured":"Edwards JCW et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572\u20132581. https:\/\/doi.org\/10.1056\/NEJMoa032534","journal-title":"N Engl J Med"},{"issue":"6","key":"4996_CR22","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/art.23498","volume":"58","author":"AM Jacobi","year":"2008","unstructured":"Jacobi AM et al (Jun. 2008) Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 58(6):1762\u20131773. https:\/\/doi.org\/10.1002\/art.23498","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4996_CR23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1194\/jlr.R200021-JLR200","volume":"44","author":"LJ Pike","year":"2003","unstructured":"Pike LJ (2003) Lipid rafts: bringing order to chaos. J Lipid Res 44(4):655\u2013667. https:\/\/doi.org\/10.1194\/jlr.R200021-JLR200","journal-title":"J Lipid Res"},{"issue":"1","key":"4996_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D (2012) CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 1(1):36. https:\/\/doi.org\/10.1186\/2162-3619-1-36","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"4996_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (Apr. 2010) Rituximab: mechanism of action. Semin Hematol 47(2):115\u2013123. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.011","journal-title":"Semin Hematol"},{"issue":"9","key":"4996_CR26","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1161\/ATVBAHA.119.311996","volume":"39","author":"P Florentina","year":"2019","unstructured":"Florentina P, Binder CJ (2019) Impact of B-cell\u2013targeted therapies on cardiovascular disease. Arterioscler Thromb Vasc Biol 39(9):1705\u20131714. https:\/\/doi.org\/10.1161\/ATVBAHA.119.311996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"4996_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2567.2002.01495.x","volume":"107","author":"JP Deans","year":"2002","unstructured":"Deans JP, Li H, Polyak MJ (2002) CD20-mediated apoptosis: signalling through lipid rafts. Immunology 107(2):176\u2013182. https:\/\/doi.org\/10.1046\/j.1365-2567.2002.01495.x","journal-title":"Immunology"},{"issue":"4","key":"4996_CR28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7555\/JBR.29.20150035","volume":"29","author":"M Bemark","year":"2015","unstructured":"Bemark M (2015) Translating transitions \u2013 how to decipher peripheral human B cell development. J Biomed Res 29(4):264\u2013284. https:\/\/doi.org\/10.7555\/JBR.29.20150035","journal-title":"J Biomed Res"},{"issue":"11","key":"4996_CR29","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1182\/blood-2004-11-4284","volume":"105","author":"GP Sims","year":"2005","unstructured":"Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE (2005) Identification and characterization of circulating human transitional B cells. Blood 105(11):4390\u20134398. https:\/\/doi.org\/10.1182\/blood-2004-11-4284","journal-title":"Blood"},{"issue":"2","key":"4996_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","volume":"24","author":"AR Rezvani","year":"2011","unstructured":"Rezvani AR, Maloney DG (Jun. 2011) Rituximab Resistance. Best Pract Res Clin Haematol 24(2):203\u2013216. https:\/\/doi.org\/10.1016\/j.beha.2011.02.009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"4996_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.seminoncol.2014.08.006","volume":"41","author":"B Bonavida","year":"2014","unstructured":"Bonavida B (2014) Postulated mechanisms of resistance of B-NHL to rituximab treatment regimens: strategies to overcome resistance. Semin Oncol 41(5):667\u2013677. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.08.006","journal-title":"Semin Oncol"},{"issue":"23","key":"4996_CR32","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/blood.V126.23.2230.2230","volume":"126","author":"Y Qian","year":"2015","unstructured":"Qian Y, Ke Q, Wang Z, Zhang B (2015) Regulation of IgD expression and its role in B cell transformation. Blood 126(23):2230\u20132230. https:\/\/doi.org\/10.1182\/blood.V126.23.2230.2230","journal-title":"Blood"},{"issue":"6","key":"4996_CR33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","volume":"58","author":"TH Ramwadhdoebe","year":"2019","unstructured":"Ramwadhdoebe TH et al (2019) Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatol Oxf Engl 58(6):1075\u20131085. https:\/\/doi.org\/10.1093\/rheumatology\/key428","journal-title":"Rheumatol Oxf Engl"},{"issue":"10","key":"4996_CR34","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1002\/art.23902","volume":"58","author":"S Dass","year":"2008","unstructured":"Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P (Oct. 2008) Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 58(10):2993\u20132999. https:\/\/doi.org\/10.1002\/art.23902","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4996_CR35","first-page":"217","volume":"37 Suppl 118","author":"S Grigoriadou","year":"2019","unstructured":"Grigoriadou S, Chowdhury F, Pontarini E, Tappuni A, Bowman SJ, Bombardieri M (2019) B cell depletion with rituximab in the treatment of primary Sj\u00f6gren\u2019s syndrome: what have we learnt? Clin Exp Rheumatol 37 Suppl 118(3):217\u2013224","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"4996_CR36","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2215\/CJN.01070118","volume":"13","author":"LM Gomez Mendez","year":"2018","unstructured":"Gomez Mendez LM et al (2018) Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol 13(10):1502\u20131509. https:\/\/doi.org\/10.2215\/CJN.01070118","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4996_CR37","doi-asserted-by":"publisher","first-page":"e0190425","DOI":"10.1371\/journal.pone.0190425","volume":"13","author":"AB Memon","year":"2018","unstructured":"Memon AB et al (2018) Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One 13(1):e0190425. https:\/\/doi.org\/10.1371\/journal.pone.0190425","journal-title":"PLoS One"},{"issue":"6","key":"4996_CR38","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1182\/blood-2003-07-2332","volume":"102","author":"TJ Hamblin","year":"2003","unstructured":"Hamblin TJ (2003) CD38: what is it there for? Blood 102(6):1939\u20131940. https:\/\/doi.org\/10.1182\/blood-2003-07-2332","journal-title":"Blood"},{"issue":"5","key":"4996_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/ejh.13042","volume":"100","author":"T Robak","year":"2018","unstructured":"Robak T, B\u0142o\u0144ski J, Skotnicki AB, Piotrowska M, Wr\u00f3bel T, Rybka J, K\u0142oczko J, Bo\u0142kun \u0141, Budziszewska BK, Walczak U, Uss A, Fidecka M, Smolewski P (2018) Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. Eur J Haematol 100(5):465\u2013474. https:\/\/doi.org\/10.1111\/ejh.13042","journal-title":"Eur J Haematol"},{"issue":"2","key":"4996_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.14670\/HH-15.573","volume":"15","author":"K Agematsu","year":"2000","unstructured":"Agematsu K (2000) Memory B cells and CD27. Histol Histopathol 15(2):573\u2013576. https:\/\/doi.org\/10.14670\/HH-15.573","journal-title":"Histol Histopathol"},{"issue":"12","key":"4996_CR41","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1002\/art.30599","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J et al (2011) Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 63(12):3692\u20133701. https:\/\/doi.org\/10.1002\/art.30599","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4996_CR42","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1002\/art.22019","volume":"54","author":"P Roll","year":"2006","unstructured":"Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P (2006) Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54(8):2377\u20132386. https:\/\/doi.org\/10.1002\/art.22019","journal-title":"Arthritis Rheum"},{"key":"4996_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fimmu.2011.00081","volume":"2","author":"Y-CB Wu","year":"2011","unstructured":"Wu Y-CB, Kipling D, Dunn-Walters DK (2011) The relationship between CD27 negative and positive B cell populations in human peripheral blood. Front Immunol 2:81. https:\/\/doi.org\/10.3389\/fimmu.2011.00081","journal-title":"Front Immunol"},{"issue":"2\u20133","key":"4996_CR44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s12026-009-8096-7","volume":"45","author":"JH Anolik","year":"2009","unstructured":"Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I (2009) Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 45(2\u20133):144\u2013158. https:\/\/doi.org\/10.1007\/s12026-009-8096-7","journal-title":"Immunol Res"},{"issue":"1","key":"4996_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.smim.2007.12.006","volume":"20","author":"I Sanz","year":"2008","unstructured":"Sanz I, Wei C, Lee FE-H, Anolik J (2008) Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 20(1):67\u201382. https:\/\/doi.org\/10.1016\/j.smim.2007.12.006","journal-title":"Semin Immunol"},{"issue":"3","key":"4996_CR46","doi-asserted-by":"publisher","first-page":"R62","DOI":"10.1186\/ar2686","volume":"11","author":"B M\u00f6ller","year":"2009","unstructured":"M\u00f6ller B et al (2009) Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther 11(3):R62. https:\/\/doi.org\/10.1186\/ar2686","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"4996_CR47","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar2789","volume":"11","author":"M Rehnberg","year":"2009","unstructured":"Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M (2009) Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 11(4):R123. https:\/\/doi.org\/10.1186\/ar2789","journal-title":"Arthritis Res Ther"},{"key":"4996_CR48","doi-asserted-by":"publisher","unstructured":"Bensalem A et al (2019) CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.14102","DOI":"10.1111\/bcp.14102"},{"key":"4996_CR49","doi-asserted-by":"publisher","unstructured":"Schwaneck EC et al (2019) T cells, natural killer cells, and \u03b3\u03b4T cells in a large patient cohort with rheumatoid arthritis: influence of age and anti-rheumatic therapy. Scand J Rheumatol:1\u20135. https:\/\/doi.org\/10.1080\/03009742.2019.1634755","DOI":"10.1080\/03009742.2019.1634755"},{"issue":"1","key":"4996_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","volume":"122","author":"T Vallerskog","year":"2007","unstructured":"Vallerskog T et al (2007) Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol Orlando Fla 122(1):62\u201374. https:\/\/doi.org\/10.1016\/j.clim.2006.08.016","journal-title":"Clin Immunol Orlando Fla"},{"issue":"3","key":"4996_CR51","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar1954","volume":"8","author":"M Vigna-Perez","year":"2006","unstructured":"Vigna-Perez M et al (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8(3):R83. https:\/\/doi.org\/10.1186\/ar1954","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"4996_CR52","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/art.22505","volume":"56","author":"I Gunnarsson","year":"2007","unstructured":"Gunnarsson I, Sundelin B, J\u00f3nsd\u00f3ttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF (2007) Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56(4):1263\u20131272. https:\/\/doi.org\/10.1002\/art.22505","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4996_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/art.20858","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP et al (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52(2):501\u2013513. https:\/\/doi.org\/10.1002\/art.20858","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4996_CR54","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00296-019-04350-4","volume":"39","author":"I Antonopoulos","year":"2019","unstructured":"Antonopoulos I, Daoussis D, Lalioti ME, Markatseli TE, Drosos AA, Taraviras S, Andonopoulos AP, Liossis SC (2019) B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis. Rheumatol Int 39(11):1889\u20131898. https:\/\/doi.org\/10.1007\/s00296-019-04350-4","journal-title":"Rheumatol Int"},{"issue":"11","key":"4996_CR55","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrrheum.2010.140","volume":"6","author":"C Mauri","year":"2010","unstructured":"Mauri C, Blair PA (2010) Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol 6(11):636\u2013643. https:\/\/doi.org\/10.1038\/nrrheum.2010.140","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"4996_CR56","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"EC Rosser","year":"2015","unstructured":"Rosser EC, Mauri C (2015) Regulatory B cells: origin, phenotype, and function. Immunity 42(4):607\u2013612. https:\/\/doi.org\/10.1016\/j.immuni.2015.04.005","journal-title":"Immunity"},{"issue":"6","key":"4996_CR57","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3892\/mco.2018.1732","volume":"9","author":"M-R Boulassel","year":"2018","unstructured":"Boulassel M-R, al Qarni Z, Burney I, Khan H, al-Zubaidi A, al Naamani A, al-Hinai H, al-Badi A, Qureshi RN, Panjwani V, al Farsi K (Dec. 2018) Levels of regulatory T cells and invariant natural killer cells and their associations with regulatory B cells in patients with non-Hodgkin lymphoma. Mol Clin Oncol 9(6):677\u2013682. https:\/\/doi.org\/10.3892\/mco.2018.1732","journal-title":"Mol Clin Oncol"},{"key":"4996_CR58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jneuroim.2015.03.016","volume":"282","author":"C Quan","year":"2015","unstructured":"Quan C et al (2015) The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. J Neuroimmunol 282:45\u201353. https:\/\/doi.org\/10.1016\/j.jneuroim.2015.03.016","journal-title":"J Neuroimmunol"},{"issue":"1","key":"4996_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/ejh.12978","volume":"100","author":"S Gudbrandsdottir","year":"2018","unstructured":"Gudbrandsdottir S, Brimnes M, K\u00f8llgaard T, Hasselbalch HC, Nielsen CH (2018) Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia. Eur J Haematol 100(1):45\u201352. https:\/\/doi.org\/10.1111\/ejh.12978","journal-title":"Eur J Haematol"},{"key":"4996_CR60","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","volume":"332","author":"S Jing","year":"2019","unstructured":"Jing S, Lu J, Song J, Luo S, Zhou L, Quan C, Xi J, Zhao C (2019) Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis. J Neuroimmunol 332:216\u2013223. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.05.004","journal-title":"J Neuroimmunol"},{"issue":"6","key":"4996_CR61","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","volume":"104","author":"E Lucchini","year":"2019","unstructured":"Lucchini E, Zaja F, Bussel J (2019) Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica 104(6):1124\u20131135. https:\/\/doi.org\/10.3324\/haematol.2019.218883","journal-title":"Haematologica"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04996-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-020-04996-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04996-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T20:27:37Z","timestamp":1613852857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-020-04996-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,22]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4996"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-04996-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,22]]},"assertion":[{"value":"17 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}